AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23343062 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginesatide (0.025 mg or 0.04 mg per kg, once a month)
Number of subjects: 983
Study 23343062 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin (0.75 μg per kg, once every 2 weeks)
Number of subjects: 983
Study 23343062 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginesatide
Number of subjects: 983
Study 22403966 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg before surgery, then twice a day for 2 days
Number of subjects: 70
Study 22403966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 22403966 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 70
Study 19777100 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group training
Number of subjects: 236
Study 19777100 — intervention group
Group type: COMPARATOR
Intervention: Self-directed Internet-based training
Number of subjects: 236
Study 17976288 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduate mental health worker case management
Number of subjects: 62
Study 17976288 — intervention group
Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 62
Study 17976288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 62
Study 15089065 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (n = 31)
Number of subjects: 100
Study 15089065 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (0.15 mg/kg, n = 39)
Number of subjects: 100
Study 15089065 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron plus dexamethasone (0.15 mg/kg ondansetron and 0.2 mg/kg dexamethasone, n = 30)
Number of subjects: 100
Study 10891023 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological questionnaires administered at baseline to parents and participants
Number of subjects: 1041
Study 10891023 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact on Family Scale
Number of subjects: 1041
Study 8629671 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWHs)
Number of subjects: 0
Study 8629671 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study 1634029 — intervention group
Group type: COMPARATOR
Intervention: Shorter appointment times
Number of subjects: 0
Study 1634029 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer appointment times
Number of subjects: 0
Study 6441236 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin base
Number of subjects: 100
Study 6441236 — intervention group
Group type: COMPARATOR
Intervention: Phenoxymethyl-penicillin (penicillin V)
Number of subjects: 100
Study 30684601 — intervention group
Group type: EXPERIMENTAL
Intervention: SEMS with tricuspid antireflux valve (SEMS-V)
Number of subjects: 60
Study 30684601 — intervention group
Group type: COMPARATOR
Intervention: SEMS without valve (SEMS-NV)
Number of subjects: 60
Study 30684601 — intervention group
Group type: COMPARATOR
Intervention: SEMS-NV
Number of subjects: 60
Study 30684601 — intervention group
Group type: EXPERIMENTAL
Intervention: SEMS-V
Number of subjects: 60
Study 29914441 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led training
Number of subjects: 72
Study 29914441 — intervention group
Group type: COMPARATOR
Intervention: Professional-led training
Number of subjects: 72
Study 27671982 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse water at 10°C
Number of subjects: 10
Study 27671982 — intervention group
Group type: COMPARATOR
Intervention: Mouthrinse water at 20°C
Number of subjects: 10
Study 27671982 — intervention group
Group type: COMPARATOR
Intervention: Mouthrinse water at 30°C
Number of subjects: 10
Study 27671982 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection time (1-6 min)
Number of subjects: 10
Study 24662422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-feed (RTF) formula
Number of subjects: 0
Study 24662422 — intervention group
Group type: COMPARATOR
Intervention: Powdered (PWD) formula
Number of subjects: 0
Study 23949586 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal suppository (metronidazole 750 mg/miconazole nitrate 200 mg) twice a day for 7 days
Number of subjects: 40
Study 23949586 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole 2 g single dose
Number of subjects: 40
Study 23949586 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal suppository (metronidazole 750 mg/miconazole nitrate 200 mg) once a day for 7 days
Number of subjects: 40
Study 20075691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool gel wrap and leg elevation intervention
Number of subjects: 60
Study 20075691 — intervention group
Group type: COMPARATOR
Intervention: Leg elevation alone intervention
Number of subjects: 60
Study 20075691 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive recruitment strategies
Number of subjects: 60
Study 20075691 — intervention group
Group type: COMPARATOR
Intervention: Proactive recruitment strategies
Number of subjects: 60
Study 20075691 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment cost
Number of subjects: 60
Study 20075691 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent by principal investigator
Number of subjects: 60
Study 17974502 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring receipt and proficiency training on its use and the Group Health secure patient website (with secure e-mail access to their healthcare provider, access to a shared medical record, prescription refill and other services)
Number of subjects: 0
Study 17974502 — intervention group
Group type: EXPERIMENTAL
Intervention: This plus pharmacist care management (collaborative care management between the patient, the pharmacist, and the patient's physician via a secure patient website and the electronic medical record)
Number of subjects: 0
Study 17974502 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 15915035 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 72
Study 15915035 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 72
Study 15915035 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam and Ketoprofen combination
Number of subjects: 72
Study 13130407 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (300 mg tablet once daily)
Number of subjects: 0
Study 13130407 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 0
Study 10995520 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone added to standard multidrug therapy (ACE inhibitor and loop diuretic)
Number of subjects: 0
Study 10995520 — intervention group
Group type: COMPARATOR
Intervention: Standard multidrug therapy (ACE inhibitor and loop diuretic)
Number of subjects: 0
Study 8637535 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (600 mg of testosterone enanthate weekly for 10 weeks)
Number of subjects: 43
Study 8637535 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone plus exercise
Number of subjects: 43
Study 8637535 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no exercise)
Number of subjects: 43
Study 8637535 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus exercise
Number of subjects: 43
Study 1323624 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet therapy (60 mg/kg every 8 h)
Number of subjects: 22
Study 1323624 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet maintenance therapy
Number of subjects: 22
Study 6437575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild surface cooling at 24 degrees C for 6 hours
Number of subjects: 0
Study 30949685 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma 25-hydroxyvitamin D concentration (25(OH)D)
Number of subjects: 2185
Study 30545387 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow concentrate (BMC) and platelet products
Number of subjects: 48
Study 30545387 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy (control group)
Number of subjects: 48
Study 30545387 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover group (after 3 months of exercise therapy)
Number of subjects: 48
Study 30545387 — intervention group
Group type: EXPERIMENTAL
Intervention: BMC treatment (after crossover)
Number of subjects: 48
Study 26750669 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 mcg/kg, iv) + midazolam (0.5 mg, iv)
Number of subjects: 44
Study 26750669 — intervention group
Group type: COMPARATOR
Intervention: Propofol (1 mg/kg, iv) + midazolam (0.5 mg, iv)
Number of subjects: 44
Study 24762111 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated saline suppression testing (SSST)
Number of subjects: 31
Study 24762111 — intervention group
Group type: COMPARATOR
Intervention: Recumbent saline suppression testing (RSST)
Number of subjects: 31
Study 22321076 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq optical laryngoscope
Number of subjects: 60
Study 22321076 — intervention group
Group type: COMPARATOR
Intervention: Conventional laryngoscopy
Number of subjects: 60
Study 20598282 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel intrauterine contraception recommendation for low socioeconomic status whites
Number of subjects: 524
Study 20598282 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine contraception recommendation for low socioeconomic status Latinas
Number of subjects: 524
Study 20598282 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine contraception recommendation for low socioeconomic status blacks
Number of subjects: 524
Study 18614450 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT intervention (6-month weekly group and individual sessions)
Number of subjects: 44
Study 18614450 — intervention group
Group type: COMPARATOR
Intervention: Support group (control condition)
Number of subjects: 44
Study 16192837 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort (LI 160)
Number of subjects: 60
Study 16192837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12625572 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrinogenation therapy (BX group)
Number of subjects: 88
Study 12625572 — intervention group
Group type: COMPARATOR
Intervention: High-dose steroid therapy (PSL group)
Number of subjects: 88
Study 10587327 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin 300 mg and isoniazid 750 mg twice weekly for 3 months (group A)
Number of subjects: 44
Study 10587327 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin 600 mg and isoniazid 750 mg twice weekly for 3 months (group B)
Number of subjects: 44
Study 10587327 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid 300 mg/day for 6 months (group C)
Number of subjects: 44
Study 8100913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous CGRP (0.6 micrograms/min for 3 h per day on 5 days)
Number of subjects: 10
Study 8100913 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 8100913 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous CGRP
Number of subjects: 10
Study 3734845 — intervention group
Group type: EXPERIMENTAL
Intervention: Human lymphoblastoid interferon (HLBI) 3 MU/m2, i.m. (weekly maintenance)
Number of subjects: 21
Study 3734845 — intervention group
Group type: COMPARATOR
Intervention: Control observation (no interferon)
Number of subjects: 21
Study 30064473 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational workshops based on the Theory of Planned Behavior (TPB), conducted over 4 years with 2 workshops per year.
Number of subjects: 744
Study 30064473 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 744
Study 27653164 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril 30 mg plus Hydrochlorothiazide 12.5 mg
Number of subjects: 482
Study 27653164 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan 150 mg plus Hydrochlorothiazide 12.5 mg
Number of subjects: 482
Study 27653164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (Zofenopril plus Hydrochlorothiazide)
Number of subjects: 482
Study 27653164 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory blood pressure monitoring (Irbesartan plus Hydrochlorothiazide)
Number of subjects: 482
Study 25483553 — intervention group
Group type: EXPERIMENTAL
Intervention: Three kiwifruits a day for 8 weeks
Number of subjects: 118
Study 25483553 — intervention group
Group type: COMPARATOR
Intervention: One apple a day for 8 weeks
Number of subjects: 118
Study 23242248 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovator cisplatin formulation
Number of subjects: 44
Study 23242248 — intervention group
Group type: COMPARATOR
Intervention: Generic cisplatin formulation
Number of subjects: 44
Study 22017935 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 450
Study 22017935 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 450
Study 19353267 — intervention group
Group type: EXPERIMENTAL
Intervention: Five session integrated intervention designed to reduce gender-based violence and HIV risk behaviors
Number of subjects: 475
Study 19353267 — intervention group
Group type: COMPARATOR
Intervention: Single 3-hour alcohol and HIV risk reduction session
Number of subjects: 475
Study 17115880 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Intensive Care (PIC) intervention
Number of subjects: 0
Study 17115880 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study 15152886 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental monitoring
Number of subjects: 0
Study 15152886 — intervention group
Group type: COMPARATOR
Intervention: Control for age, gender, drinking at baseline, and being in various high-risk situations
Number of subjects: 0
Study 11182467 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI volumetric measures of hippocampal volume
Number of subjects: 39
Study 11182467 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hippocampal volume
Number of subjects: 39
Study 11182467 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hippocampal volume
Number of subjects: 39
Study 11182467 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal asymmetry
Number of subjects: 39
Study 9817475 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (6.25 mg test dose, followed by 12.5 mg 3 times daily for 24 hours and 25 mg 3 times daily for the next 24 hours)
Number of subjects: 60
Study 9817475 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (25 mg/day increased to 50 mg after 24 hours)
Number of subjects: 60
Study 9817475 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril plus Furosemide (40 mg in the morning)
Number of subjects: 60
Study 9817475 — intervention group
Group type: COMPARATOR
Intervention: Continuous ISDN only (group A)
Number of subjects: 60
Study 9817475 — intervention group
Group type: COMPARATOR
Intervention: Captopril (group B)
Number of subjects: 60
Study 9817475 — intervention group
Group type: COMPARATOR
Intervention: Captopril plus Furosemide (group C)
Number of subjects: 60
Study 9817475 — intervention group
Group type: COMPARATOR
Intervention: Losartan (group D)
Number of subjects: 60
Study 8291700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg long‐acting orally 12 h before surgery and 10 mg sublingually 1.5 h before surgery
Number of subjects: 30
Study 8291700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg sublingually just before induction of anesthesia
Number of subjects: 30
Study 8291700 — intervention group
Group type: COMPARATOR
Intervention: No nifedipine (control)
Number of subjects: 30
Study 2557183 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin (6 micrograms/kg, subcutaneously)
Number of subjects: 33
Study 2557183 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg orally, 10 and 2 hours before dosing)
Number of subjects: 33
Study 2557183 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate (12.6 gm)
Number of subjects: 33
Study 2557183 — intervention group
Group type: COMPARATOR
Intervention: Aluminum hydroxide (120 cc)
Number of subjects: 33
Study 2557183 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet
Number of subjects: 33
Study 2557183 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet
Number of subjects: 33
Study 2557183 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet
Number of subjects: 33
Study 2557183 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 33
Study 28302116 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning training and education
Number of subjects: 247
Study 28302116 — intervention group
Group type: COMPARATOR
Intervention: face-to-face group training
Number of subjects: 247
Study 28302116 — intervention group
Group type: COMPARATOR
Intervention: regular care
Number of subjects: 247
Study 25792492 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once weekly
Number of subjects: 109
Study 25792492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 23275593 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE4 carriers
Number of subjects: 18
Study 23275593 — intervention group
Group type: COMPARATOR
Intervention: Non-APOE4 controls
Number of subjects: 18
Study 21984584 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion during hypoglycemia
Number of subjects: 10
Study 21984584 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion during euglycemia
Number of subjects: 10
Study 21984584 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion during hyperglycemia
Number of subjects: 10
Study 21984584 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion during hypoglycemia
Number of subjects: 10
Study 21984584 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion during euglycemia
Number of subjects: 10
Study 21984584 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion during hyperglycemia
Number of subjects: 10
Study 18293187 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (DTFC)
Number of subjects: 32
Study 18293187 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost/timolol fixed combination (LTFC)
Number of subjects: 32
Study 16501248 — intervention group
Group type: EXPERIMENTAL
Intervention: DNMT3b-c31721t SNP
Number of subjects: 9054
Study 16501248 — intervention group
Group type: EXPERIMENTAL
Intervention: PRDM2-c99243 t SNP
Number of subjects: 9054
Study 16501248 — intervention group
Group type: EXPERIMENTAL
Intervention: t105413c SNP
Number of subjects: 9054
Study 16501248 — intervention group
Group type: EXPERIMENTAL
Intervention: EHMT1-g-9441a SNP
Number of subjects: 9054
Study 16501248 — intervention group
Group type: EXPERIMENTAL
Intervention: EHMT1-g41451t SNP
Number of subjects: 9054
Study 16501248 — intervention group
Group type: EXPERIMENTAL
Intervention: EHMT2-S237S SNP
Number of subjects: 9054
Study 16501248 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall significant SNPs
Number of subjects: 9054
Study 16501248 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygotes for rare alleles of EHMT1, EHMT2, and PRDM2
Number of subjects: 9054
Study 14511868 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural
Number of subjects: 128
Study 14511868 — intervention group
Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 128
Study 14511868 — intervention group
Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 128
Study 10894313 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 67
Study 10894313 — intervention group
Group type: COMPARATOR
Intervention: No weight loss intervention (Control)
Number of subjects: 67
Study 9362356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial injection of 131I-labeled Lipiodol (60 mCi; 2.2 GBq) (n = 73)
Number of subjects: 142
Study 9362356 — intervention group
Group type: COMPARATOR
Intervention: Chemoembolization (70 mg cisplatin) (n = 69)
Number of subjects: 142
Study 9362356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial injection of 131I-labeled Lipiodol (n = 73)
Number of subjects: 142
Study 9362356 — intervention group
Group type: COMPARATOR
Intervention: Chemoembolization (n = 69)
Number of subjects: 142
Study 8402090 — intervention group
Group type: EXPERIMENTAL
Intervention: Air plethysmography
Number of subjects: 113
Study 8402090 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory venous pressure measurement
Number of subjects: 113
Study 3511878 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride treatment
Number of subjects: 22
Study 3511878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 3511878 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine therapy after crossover from placebo
Number of subjects: 22
Study 3511878 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall improvement with desipramine
Number of subjects: 22
Study 3511878 — intervention group
Group type: EXPERIMENTAL
Intervention: Global clinical status improvement
Number of subjects: 22
Study 3511878 — intervention group
Group type: EXPERIMENTAL
Intervention: Zung depression scores
Number of subjects: 22
Study 3511878 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimia symptom scale
Number of subjects: 22
Study 3511878 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine treatment
Number of subjects: 22
Study 3511878 — intervention group
Group type: EXPERIMENTAL
Intervention: One-month follow-up data
Number of subjects: 22
Study 29518488 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet I - moderate in carbohydrate
Number of subjects: 280
Study 29518488 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet II - normal in carbohydrate
Number of subjects: 280
Study 27297936 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 220
Study 27297936 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 220
Study 24686885 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of modelled CVD risk at baseline
Number of subjects: 2418
Study 24686885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of modelled CVD risk at baseline
Number of subjects: 2418
Study 24686885 — intervention group
Group type: COMPARATOR
Intervention: Socioeconomic status
Number of subjects: 2418